ABSTRACT. The mechanisms of valproate-associated carAbbreviations nitine deficiency are controversial. The urinary excretion of valproylcarnitine is insufficient to account for tissue VPA, valproic acid TDW, toxic dose of VPA resulting in 50% suppression of carnitine depletion. T o esplore this mechanism, we studied carnitine uptake the effects of val~roic acid (VPA) on carnitine u~t a k e in cultured human skin fibroblasts by the method o i Tein et al. (Pediatr Res 28:247-255. 1990 ). Fibroblasts were preincubated with varying concentratibns (0-2000 p h l ) of "PA for 1, 3, 5, 7, 10, 14, 21, and 28 d and then incubated Serum carnitine c o m m o n 1~ accompany fixed carnitine concentrations of50 p h~ (normal phys-long-term VPA therapy for epilepsy (1) (2) (3) (4) (5) (6) (7) (8) . Less COn~mon but more serious side effects of VPA include a Reye-like syndrome, iolOgic 20 phl (as seen in idiosynCmtic and life-threatening hepatotoxicity (distinct from tine disorders), Or phl (as seen in the plasma dose-related hepatotoxicity), and pancreatitis (8-16). membrane carnitine transport defect). There was an excarnitine deficiency in patients with epilepsy may be due to ponential dose-dependent decrease in carnitine uptake with multiple causes, including nutritional deficiency, an underlying increasing VPA concentrations, and the relative inhibitory inborn error of metabolism, and VPA therapy. N~~~~~~~ effect Was the Same for all three carnitille ~~~~e~t r a t i~n~.
have shown a significant decrease in total and/or free serum
The mean Percentages f S D (n -1) of residual carnitine carnitine concentrations in patients taking multiple anticonvuluptake for all combined reinc cub at ion periods (1-28 d) sants including VPA (3, 17-21) or VPA alone (3). However, in and combined carnitine concentrations (5,20, and 50 pmoll one study of 2 1 children on VPA, the mean serum carnitine L) with increasing concentrations of VPA varied from 83.4 concentration did not correlate with either oral VPA dose or + 2.6% (10 p h l VPA) to 56.7 f 0.1% (500 p M ) to 19.8 f serum VPA concentration (22) . Even in the presence of normal 1.3% (2000 pM). The degree of inhibition was directly serum carnitine concentrations, isolated muscle carnitine defiproportional to the time of VPA preincubation and parallel ciency was documented in three children receiving chronic VPA for all three carnitine concentrations; the longer the prein-therapy for intractable seizures (23). Given that 90% of body cubation period, the lower the toxic dose of Vpti (to a carnitine stores are contained within skeletal muscle (24), this minimum of 450 L t~) , resulting in a 50% suppression of finding suggests that serum carnitine concentrations are not carnitine uptake ( T D~) . ~h~ mean T D~ of the always informative and that muscle camitine concentrations may carnitine concentrations for increasing preincubation provide a more accurate reflection of the carnitine status of the riods of VPti varied from 1898 214 to 447 patient. Again, no correlation was found in this study between pM (28 d), tapering an asymptote of 450 pM VPA dose and degree of carnitine depletion, suggesting other when the preincubation period exceeded 1 4 d. This in virro mediating factors.
There may be multiple mechanisms of VPA-associated carni-TD% v a l~~ may be com~arable the in thera~eutic tine deficiency including a defect in hepatic biosynthesis, an range of serum concentrations (350-700 pmollL) for increase in renal excretion, or a decrease in carnitine transport anticonvulsant therapy. We conclude that one mechanism into tissues. ~~~~i~~~~ of carnitine biosynthesis in liver (25, by which long-term VPA therapy induces serum and tissue 26) would have to be accompanied by a nutritional deficiency to carnitine depletion is through inhibition of plasmalemmal significantly diminish total body carnitine stores because approxcarnitine uptake, including decreased renal reabsorption of imately 75% of carnitine is obtained from the diet (24). Furtherfree carnitine. This effect is directly proportional to the more, camitine deficiency can occur without significant hepatic duration of exposure and concentration of VPA. (Pediatr dysfunction, implying that other mechanisms are involved. Res 34: 281-287,1993) The renal loss of carnitine as valproylcarnitine has been examined by a number of investigators (19, 22, 27 crease in urinary carnitine excretion has been documented in one patient with VPA-associated hepatotoxicity (28). However, it is still unproven whether long-term VPA therapy with continued urinary excretion of valproylcarnitine depletes total body stores of carnitine leading to a deficiency state. A defect in tissue carnitine transport could explain both serum depletion caused by decreased renal tubular reabsorption of free carnitine and muscle depletion caused by decreased muscle uptake. Evidence is emerging that muscle, kidney, and fibroblasts share a common plasmalemmal carnitine transporter (29, 30) . Fibroblasts have become a useful model to examine the "musclekidney" carnitine transport system (30, 3 I). Therefore, we studied the effect of increasing VPA concentrations and increasing time periods of VPA preincubation on carnitine uptake in cultured human skin fibroblasts. To determine the relative severity of the VPA effect in different clinical conditions, we also varied the carnitine concentrations in the incubation medium to simulate serum carnitine concentrations seen in normal controls and in primary and secondary carnitine deficiency disorders.
MATERIALS AND METHODS
All studies were performed with the approval of the Institutional Review Board of The Hospital for Sick Children, Toronto. Carnitine uptake studies were performed in control cultured skin fibroblasts with documented normal carnitine uptake. Control fibroblasts were obtained from the Human Genetic Mutant Cell Repository, Coriell Institute for Medical Research, Camden, NJ. The uptake of carnitine was investigated by the method of Tein et al. (30) . Control fibroblasts (passage numbers 6-12) were plated onto 9.5-cm six-well plates (Gibco Laboratories, St. Lawrence, MA) and allowed to grow to confluence in RPMI 1640 medium supplemented with 10% FCS (medium total carnitine, 2 pmol/L). L-[methyl-'Hlcarnitine hydrochloride was purchased from Amersham, Arlington Heights, IL, and L-carnitine was a gift from Sigma-Tau Pharmaceuticals, Pomezia, Italy. Cellbound radioactivity was determined in 800 pL of the final fibroblast hydrolysate using Aquasol-2 with a counting efficiency of 60%. Cell protein was measured in the remaining 200 pL of the hydrolysate for each individual plate by the method of Lowry et al. (32) . VPA (2-propylpentanoic acid) was used as supplied from Sigma Chemical Co., St. Louis, MO. Experiments with VPA were run in parallel with a standard control carnitine uptake study without VPA. Nonspecific uptake was determined at 10 mmol/L carnitine. VPA concentrations in the preincubation medium of RPMI 1640 and 10% FCS were fixed at 0, 100,200, 300, 500, 700, 900, 1 100, 1300, 1500, 1700, and 2000 pmol/L. At the beginning of the uptake study, the plates were thoroughly washed four times with PBS to remove all excess FCS. The individual wells were then incubated with the same predetermined concentrations of VPA, in RPMI without FCS, and a fixed carnitine concentration of 5, 20, or 50 pmol/L, for the measurement of ['HI-L-carnitine uptake in vitro. The VPA preincubation periods were varied from 4 h (actual incubation period ofuptake study) to 1,3, 5,7, 10, 14,21, and 28 d. Reproducibility of results was confirmed by repeat experiments using the identical VPA concentration, time period of VPA preincubation, and carnitine substrate incubation concentration, on three separate days. Specific uptake of radioactivity was used to calculate the rates of total carnitine uptake. Apparent Km and V,,, values for standard carnitine uptake studies were obtained by linear regression analysis of Lineweaver-Burk plots.
Carnitine uptake was examined against increasing VPA preincubation concentrations for each of the three carnitine incubation concentrations (5, 20, 50 pM) under eight fixed VPA preincubation periods (1-28 d) for triplicate experiments (72 analyses). The curves of residual carnitine uptake with increasing concentrations of VPA were plotted together for the different VPA preincubation periods. The mean of the residual carnitine uptake from all VPA incubation periods was determined for each of the three carnitine concentrations and plotted against increasing concentrations of VPA to demonstrate the net effect of increasing VPA concentrations. The TDso of VPA resulting in a 50% suppression of carnitine uptake was determined by nonlinear regression analysis of dose-response curves plotting carnitine uptake versus increasing VPA concentrations. The statistical nonlinear regression analysis program (Systat 5.0) was obtained from Systat Inc., Evanston, 1L. These dose-response curves were individually analyzed for each of the three carnitine incubation concentrations (5, 20, 50 pM) under eight fixed VPA preincubation periods (1-28 d) for triplicate experiments (72 analyses). The mean TDSo (triplicate experiments) for the individual carnitine concentrations were then plotted against increasing time of VPA preincubation to establish the time period of maximum effect.
RESULTS
During the 4-h incubation period of the uptake study without any preincubation, VPA had no significant effect on carnitine uptake at the lower concentrations and only a minor effect at the highest concentration of 2000 pmol/L (15% reduction in carnitine uptake). Significant effects were initially demonstrated with a preincubation period of 24 h (Fig. la) . The curves of residual carnitine uptake with increasing concentrations of VPA (0 to 2000 pmol/L) were plotted for each of the three carnitine incubation concentrations (5, 20, 50 pmol/L) under each of the eight VPA preincubation periods (I -28 d) using nonlinear regression analysis.
To examine the rate of decline with increasing VPA preincubation periods, the individual curves from four preincubation periods for a fixed carnitine incubation concentration (c.g. 50 pmol/L) were collated on the same graph as shown in Figure l (Fig. 2) . The mean values are listed in Table 1 with the calculated percentages of residual uptake. There was no significant difference in the relative rates of decline of carnitine uptake with increasing VPA concentrations at the different carnitine concentrations. Although the percentage decrease of carnitine uptake was not affected by the initial carnitine concentration, the absolute values of carnitine uptake were lowest at 5 pmol/L carnitine concentration, intermediate at 20 pmol/L, and highest at 50 pmol/L concentration. (Fig. 3) . The TDso of VPA resulting in a 50% suppression of carnitine uptake was determined by nonlinear regression analysis of the dose-response curves for the individual carnitine concentrations and the means determined. The degree of inhibition ofcarnitine uptake was directly proportional to the time of VPA incubation, and parallel for all three carnitine concentrations (Fig. 4, Table 2) ; the longer the preincubation period, the lower the TDso of VPA that tapered toward an asymptote of 450 pM when the preincubation period was r 14 d. The maximum effect of VPA preincubation time on carnitine uptake, regardless of the carnitine incubation concentration, was reached by 10-14 d of VPA exposure, beyond which there was no significant additional effect on the TDs0. Of note, the mean in vitro TDSo values for VPA preincubations of 7-28 d, namely 560-450 @mol/L, may be comparable to the in viva therapeutic range of serum VPA concentrations (350-700 pmol/L), which is used as a general guideline for VPA anticonvulsant therapy in epileptic patients. Preincubation periods of 1-28 d in standard control uptake plates without VPA (run in parallel with the VPA experiment plates) showed no significant decrease of carnitine uptake.
DISCUSSION
Carnitine concentrations in most tissues, except brain, are 20-to 50-fold higher than in serum (33). Carnitine uptake is mediated by a transport system, apparently driven by a large sodium potential across the plasma membrane (34, 35) and generally held to be energy-dependent (36) (37) (38) . In studies of children with primary systemic carnitine deficiency, a genetically determined defect in plasmalemmal carnitine transport has been documented in cultured skin fibroblasts (29, 30) . Clinically, these children present with hypotonia, weakness, lethargy, cardiomyopathy, fasting hypoglycemia, hypoketotic encephalopathy, and failure to thrive. Because these patients have a markedly decreased renal threshold for carnitine and are incapable of fully restoring muscle carnitine concentrations despite high-dose oral carnitine supplementation and almost complete restoration of normal serum carnitine concentrations, it has been postulated that muscle, kidney, and fibroblasts share a common plasmalemmal carnitine transporter (29, 30) . This concept is supported by the similar Km values for carnitine uptake in cultured muscle (1.90 f 1.38 pM) (39), human heart cells (4.8 & 2.2 pM) (40), and skin fibroblasts (5.5 * 0.58 pM) (30), which are very different from the Km values observed in human liver (500 pM) and brain (> 1000 pM) (41). A VPA-associated defect in carnitine transport could mimic the genetically determined defect in plasmalemmal carnitine transport and could result in decreased renal tubular reabsorption of free carnitine and explain the isolated deficiency of muscle carnitine documented in three patients on long-term VPA therapy (23).
We therefore investigated the effect of increasing concentrations and exposure periods of VPA on plasmalemmal carnitine uptake in cultured control human skin fibroblasts at three carnitine concentrations. There was an exponential dose-dependent decrease in carnitine uptake with increasing VPA concentration. The relative inhibitory effect of increasing VPA concentrations on carnitine uptake was the same for all three carnitine concentrations. The degree of inhibition was directly proportional to No significant effect on carnitine uptake was noted after 4 h of incubation with VPA, with the exception of a minor decrease (1 5%) in uptake at the highest concentration of 2000 pmol/L, which is three times the normal therapeutic range. Thus, significant VPA inhibition of carnitine uptake appears to require a period of several days and reaches maximum effect by approximately 10-14 d. This could be compatible with the observation that 75% of cases of idiosyncratic fatal hepatotoxicity occur within the first 3 mo of therapy (42) .
There are at least four different mechanisms by which VPA can interfere with carnitine uptake. One mechanism could be the direct inhibition of carnitine uptake by valproylcarnitine. VPA (2-propylpentanoic acid), an eight-carbon fatty acid, is assumed to pass freely through the mitochondrial membrane in a carnitine-independent manner (43). VPA is then probably converted into its activated intermediate, valproyl-CoA (2-propyl-pentanoyl-CoA), as demonstrated in rat liver mitochondria (43). As proposed by Millington el al. (27) , valproyl-CoA is probably converted into valproylcarnitine by one or more of the carnitine acyltransferases, predominantly carnitine octanoyltransferase, at the inner surface of the inner mitochondrial membrane. We suggest that valproylcarnitine may then be transported out of the mitochondrion, leaving behind free CoA within the mitochondria. The valproylcarnitine may diffuse across the plasmalemma and then interfere with tissue free carnitine transport or renal tubular reabsorption of free carnitine. Depressed renal tubular reabsorption of free carnitine has been documented by Matsuda and Ohtani (28) in children receiving VPA therapy.
Stanley et al. (44) examined the renal free carnitine threshold (plasma level at which urinary free carnitine fell below 5% of the filtered load) and also found that it was below the normal range
